Progress of programmed death receptor 1 inhibitors in treatment of relapsed/refractory Hodgkin lymphoma
10.3760/cma.j.cn115355-2020080500436
- VernacularTitle:程序性死亡受体1抑制剂治疗复发难治霍奇金淋巴瘤的研究进展
- Author:
Beizeng WU
;
Tao WANG
;
Liangming MA
- From:
Cancer Research and Clinic
2021;33(3):236-240
- CountryChina
- Language:Chinese
-
Abstract:
In the treatment of Hodgkin lymphoma (HL), it is important to avoid delayed side effects while improving efficacy, the immunotherapy provides an excellent option. The programmed death receptor 1 (PD-1) inhibitors are effective drugs for the treatment of relapsed/refractory HL. Meanwhile, the high effectiveness and tolerance of PD-1 inhibitors also provide the possibility for combination therapy. This article reviews the research progress of PD-1 inhibitors in the treatment of relapsed/refractory HL.
